The healing of gastric ulcer is a complicated process that involves the proliferation of epithelial and endothelial cells and the concerted actions of a wide range of growth factors. Prostaglandins play an important role in ulcer healing. Expression of cyclooxygenase-2 (COX-2) is markedly upregulated around the margins of gastric ulcers and its inhibition leads to a delay of ulcer healing. Several of the growth factors that promote ulcer healing may work in part through COX-2-dependent mechanisms. Angiogenesis, which is crucial to ulcer healing, is tightly regulated by growth factors. Treatment with selective COX-2 inhibitors appears to alter the balance of serum levels of growth factors, favoring an inhibition of angiogenesis. Given the importance of COX-2 in regulating ulcer healing, caution should be taken in the use of selective inhibitors of COX-2 by patients at risk of ulcer disease.
INTRODUCTION
The ability of nonsteroidal anti-inflammatory drugs (NSAIDs) to induce ulcers in the upper gastrointestinal (GI) tract is well recognized and has provided an impetus for the development of GI-sparing anti-inflammatory drugs. An additional problem associated with the use of these drugs is their ability to interfere with the healing of pre-existing ulcers. This phenomenon has been well documented both in humans [1, 2] and in experimental models of gastric ulcer [3] [4] [5] [6] . This effect of NSAIDs presents a dilemma in terms of the treatment of patients with arthritis, who develop a gastric or duodenal ulcer. The delaying effect of the NSAID on ulcer healing, and the possibility that this could lead to lifethreatening hemorrhage frequently requires the patient to cease taking the NSAID. The ability of NSAIDs to delay ulcer healing is generally believed to be a direct consequence of the inhibitory effects of these drugs on prostaglandin synthesis, but the relative contribution of the different isoforms of prostaglandin synthetase to this process has only recently been appreciated.
THE PROCESS OF ULCER HEALING
Ulcer is defined as a break in lining of the stomach that extends through the muscularis mucosae. Ulcer healing is an active and complicated process of filling the mucosal defect with proliferating and migrating epithelial cells and connective components, so as to reconstruct the mucosal architecture [7] . Tissue repair is initiated with the aggregation of platelets, formation of a fibrin clot, and the release of growth factors from the activated coagulation pathways, injured cells, platelets, and extracellular matrix, followed by migration of inflammatory cells to the wound site. Thereafter, epithelial cells migrate over the damage, *Address correspondence to this author at the Department of Pharmacology & Therapeutics, University of Calgary, 3330 Hospital Drive NW Calgary, Alberta, T2N 4N1, Canada; Tel: (1) 403-220-4539; FAX: (1) 403-270-3353; E-mail: wallacej@ucalgary.ca angiogenesis is initiated, and fibroblasts deposit and remodel the granulation tissue. Critical to the repair process is the growth of new blood vessels. Angiogenesis occurs through the migration and division of endothelial cells, which gradually form tubes that will become the new blood vessels. Just as there are arrays of growth factors that will drive epithelial proliferation, there are numerous factors that regulate the process of angiogenesis. Endothelial cells and vascular smooth muscle cells produce some of these factors in the region of the injury. Other angiogenic factors are delivered to the site of injury via the platelets. Figure (1) shows the natural course of healing of experimental ulcers in rats, and the dramatic increase in angiogenesis that occurs during this healing process.
Ulcer healing can be adversely affected by a number of factors, most notably the presence of acid in the lumen of the stomach and colonization of the ulcer bed by bacteria. The evidence suggesting that acid can delay ulcer healing consists mainly of studies demonstrating that ulcer healing is accelerated by anti-secretory agents, such as histamine H2 receptor antagonists and proton pump inhibitors [8] . In a rat model of gastric ulcer, the ulcer bed was found to be rapidly colonized by a number of species of bacteria [9] . Treatment with antibiotics accelerated ulcer healing. The bacteria were able to colonize the ulcer bed in part because of the relatively high pH in that region as compared to the pH of the luminal contents.
Prostaglandins also appear to play a key role in ulcer healing, as administration of prostaglandin analogs to patients with ulcers can accelerate their healing [10] , while inhibition of endogenous prostaglandin synthesis, with NSAIDs, results in delayed ulcer healing. Indeed, NSAID administration can greatly reduce the effectiveness of H2 antagonists and proton pump inhibitors to promote ulcer healing [11] . The discovery in the early 1990s of a second isoform of the key enzyme for prostaglandin synthesis [12, 13] , cyclooxygenase (COX), led to a renewed interest in the role of prostaglandins in ulcer healing. While COX-1 appears to be the isoform that produces the majority of the prostaglandins in the normal stomach, it is the so-called 'inducible' isoform, COX-2, that appears to be the most important factor in the promotion of ulcer healing.
ROLE OF COX-2 IN ULCER HEALING
Studies in the mid-1990s of the role of COX-2 in the resolution of experimental colitis [14] provided the first suggestion that this enzyme played a key role in ulcer healing. Treatment of rats with colitis with selective COX-2 inhibitors resulted in a profound exacerbation of the colitis, leading to deeper penetration of colonic ulcers, perforation and death [14] . In 1997, Mizuno and colleagues demonstrated that a COX-2 was strongly expressed at the margin of experimental ulcers in mice, and that administration of a selective COX-2 inhibitor delayed healing of the ulcers. Other investigators subsequently confirmed this finding using various rodent models of gastric ulceration [6, [15] [16] [17] [18] [19] . The retardation of gastric ulcer healing by selective COX-2 inhibitors was comparable to that produced by conventional NSAIDs [6] . Interestingly, COX-2 is most strongly expressed in fibroblasts, monocytes/macrophages and granulocytes, the cells that comprise the granulation tissue at the base of an ulcer [20] . The mechanisms through which prostaglandins contribute to ulcer healing are not fully understood While initially it was believed that COX-2 contributed to ulcer healing purely through the production of prostaglandins, more recent studies have strongly suggested that inhibitors of COX-2 cause retardation of ulcer healing through both prostaglandin-dependent and -independent pathways. For example, Hirose [21] reported that a selective COX-2 inhibitor (JTE522) could inhibit proliferation of gastric epithelial cells, but there was a disassociation between the effects of this drug on proliferation and its effects on PGE 2 synthesis. Addition of fetal calf serum to the culture gastric epithelial cells caused increased COX-2 expression. Addition of arachidonic acid increased prostaglandin synthesis and promoted epithelial proliferation. When they added both arachidonic acid and the selective COX-2 inhibitor, they observed a marked retardation of healing, but only a partial suppression of PGE 2 synthesis. Thus, there was a separation of effects on healing and on prostaglandin synthesis, suggesting that the COX-2 inhibitor produced some of its detrimental effects on epithelial proliferation through a prostaglandin-independent mechanism.
Brzozowski [18] arrived at a similar conclusion from in vivo studies of a rat gastric ulcer model. They compared the effects of several NSAIDs and selective COX inhibitors in the ulcer model. After several days of treatment, they measured ulcer area, rates of blood flow at the margin of the ulcers and PGE 2 synthesis. Conventional NSAIDs (indomethacin, aspirin) and a selective COX-1 inhibitor (resveratrol) delayed ulcer healing, reduced blood flow at the ulcer margin and markedly suppressed PGE 2 synthesis in both ulcerated and non-ulcerated tissue. In contrast, selective COX-2 inhibitors (rofecoxib; NS-398) delayed ulcer healing, caused only a moderate decrease in PGE 2 synthesis in the non-ulcerated tissue (but more profound at the ulcer margin) and significantly reduced gastric blood flow. Thus, there was once again an apparent separation of inhibition of prostaglandin synthesis and effects on ulcer healing, suggesting that these drugs inhibit the healing process in part through PG-independent actions.
There is very strong evidence to suggest that one of the most important targets for selective COX-2 inhibitors in terms of retardation of ulcer healing is the process of angiogenesis. Angiogenesis is a crucial component of the ulcer healing process and has been shown to be inhibited by direct effects of COX-2 inhibitors on the endothelium [22] and indirectly, through effects on circulating levels of proand anti-angiogenic factors [6] . Jones demonstrated that there is a role for both COX-1 and COX-2 in regulating angiogenesis at the level of the endothelial cell, and it involves inhibition of MAP kinase (ERK2) activity and interference with ERK nuclear translocation. They further demonstrated that these effects are having prostaglandindependent and -independent components.
Growth Factors, COX-2 and Ulcer Healing
Several growth factors have been shown to promote the healing of gastric ulcers in experimental models, including epidermal growth factor, transforming growth factor-β, basic fibroblast growth factor (bFGF), gastrin and hepatocyte growth factor (HGF) [7] . The actions of at least some of these growth factors may be mediated via effects on COX-2 expression in the tissue surrounding an ulcer. For example, bFGF and HGF have been shown to up-regulate COX-2 expression in rat gastric epithelial cells [23, 24] . Local injections of HGF around ulcers in the rat stomach were also found to result in up-regulation of COX-2. Moreover, the accelerated healing that was achieved following injection of HGF was blocked when a selective COX-2 inhibitor was administered [25] . Similar results were obtained when gastrin was injected rather than HGF [25] . Gastrin has recently been demonstrated to up-regulate COX-2 expression in the rat stomach and to increase resistance of the gastric mucosa to damage [26] .
Platelets, Angiogenesis and Ulcer Healing
In addition to their well-known effect in the blood clotting process, platelets make an important contribution to wound healing. Platelets contain both growth-promoting and -inhibiting substances. In the context of gastric ulcers, platelets appear to act primarily to promote healing. This is best exemplified by the observation that immunodepletion of platelets results in significant inhibition of angiogenesis and a delay of ulcer healing [27] . As mentioned above, angiogenesis is a pivotal component of ulcer healing and is regulated by pro-and anti-angiogenic factors. The levels of pro-and anti-angiogenic factors within platelets and in the serum do not remain static. Indeed, in rats with gastric ulcers, the ratio of serum levels for the pro-angiogenic factor, vascular endothelial growth factor (VEGF), to the antiangiogenic factor, endostatin, is increased (Fig. 2) . Thus, there is a shift in the balance of pro-versus anti-angiogenic factors, favoring the progression of angiogenesis (and, therefore, ulcer healing) [27] . Certain drugs, including selective COX-2 inhibitors, can influence platelet and serum levels of these regulators of angiogenesis, and thereby affect gastric ulcer healing. Treatment of rats with ulcers with ticlopidine (and ADP receptor antagonist) caused a dramatic shift in the serum and platelet levels of these angiogenesisregulating factors in the opposite direction. Ticlopidine increased serum and platelet endostatin and decreased serum and platelet VEGF levels (Fig. 2) . Moreover, ticlopidine significantly delayed healing of the ulcers. Similar effects were observed with clopidogrel, another anti-platelet drug with a similar mechanism of action to ticlopidine.
COX-2 and the Angiogenic Balance
The studies described above demonstrated that certain drugs could cause a shift in the balance of angiogenic factors found in platelets and the serum. The presence of an ulcer appeared to cause a shift in the pro-angiogenesis direction, while treatment with ticlopidine caused a shift in the antiangiogenesis direction. Given the substantial evidence that selective COX-2 inhibitors could delay ulcer healing, we investigated the possibility that these drugs might exert effects on the angiogenic balance similar to what we had seen with ticlopidine. We compared the effects of a selective COX-2 inhibitor, celecoxib, to those of a conventional NSAID (flurbiprofen) and a nitric oxide-releasing derivative of flurbiprofen (HCT-1026) [6] . Rats with gastric ulcers induced by serosal application of acetic acid were treated daily with one of the test drugs for a week. The extent of ulcer healing and the serum and platelet levels of VEGF and endostatin were then examined. As shown in Fig. (3) , treatment with celecoxib or flurbiprofen resulted in a significant delay in ulcer healing relative to the group treated with vehicle. Moreover, there was significantly less angiogenesis in the ulcer bed in those groups that in the vehicle-treated group. In contrast to the effects of celecoxib and flurbiprofen, HCT-1026 did not delay ulcer healing and did not inhibit angiogeneis, despite inhibiting gastric prostaglandin synthesis as effectively as the other two drugs. None of the test drugs affected platelet levels of VEGF or endostatin, but they did influence serum levels of these angiogenic factors. All three of the COX inhibitors caused a significant increase in serum endostatin levels, which would be consistent with reduced angiogenesis and delayed ulcer healing. However, in the case of rats treated with HCT-1026, there was a parallel increase in serum levels of VEGF. Thus, with HCT-1026, but not with celecoxib or flurbiprofen, the balance of serum levels of endostatin and VEGF was maintained in a pro-angiogenic state, as opposed to be shifted to an anti-angiogenic state. In vitro studies of human Fig. (2) . Serum levels of a pro-angiogenic factor (VEGF) and an anti-angiogenic factor (endostatin) in the absence and presence of an ulcer, and the effects of treatment with ticlopidine. The presence of an ulcer in the stomach results in a significant decrease in serum endostatin levels, and an increase in serum VEGF levels ( # p<0.05 versus the "no ulcer" group). Thus, there is a switch in the angiogenic balance to favour healing. Treatment with ticlopidine (300 mg/kg) each day for a week results in prevention of the pro-angiogenic switch (*p<0.05 **p<0.01 versus the "ulcer + vehicle" group). Such treatment results in a significant delay in ulcer healing [27] . umbilical vein endothelial cell proliferation and apoptosis confirmed these findings [6] .
SUMMARY
Healing of gastric ulcers can be influenced by a number of exogenous and endogenous factors. The regulation of epithelial and endothelial proliferation is critical in determining the rate of ulcer healing. Many growth factors can influence ulcer healing through effects on epithelial and/or endothelial proliferation. NSAIDs and selective inhibitors of COX-2 can markedly retard the healing of gastric ulcers, by inhibiting both epithelial proliferation and angiogenesis. Some growth factors appear to act in part through induction of COX-2 expression at the ulcer site. In addition, NSAIDs and selective COX-2 inhibitors can modify the release of key growth factors into the serum, and thereby affect ulcer healing. Further studies are required to better understand the mechanisms through which inhibition of COX-2 causes a retardation of ulcer healing. In the meantime, the potential of selective COX-2 inhibitors to interfere with mucosal repair should be kept in mind when considering options for the treatment of patients in whom the healing of ulcers is a concern. Fig. (3) . Effects of daily treatment with a selective COX-2 inhibitor (celecoxib), a conventional NSAID (flurbiprofen) or a nitric oxidereleasing derivative of flurbiprofen (HCT-1026) on gastric ulcer healing and angiogenesis in rats. Celecoxib and flurbiprofen significantly interfered with ulcer healing and reduced the extent of angiogenesis, relative to the vehicle-treated group (*p<0.05, **p<0.01). In contrast, treatment with HCT-1026 did not interfere with ulcer healing or angiogenesis.
